Aberrant ROCK activation promotes the development of type I diabetes in NOD mice

Cellular Immunology

Volumn 266, Issue 2, 2011, Pages 111-115

  Biswas, Partha S ^a   Gupta, Sanjay ^a   Chang, Emily ^a   Bhagat, Govind ^a   Pernis, Alessandra B ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

IL 17; IL 21; Signaling pathways; Type 1 diabetes

Indexed keywords

INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 17; INTERLEUKIN 21; PROTEIN; PROTEIN ROCK2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; PROTEIN FUNCTION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; FEMALE; INTERFERON REGULATORY FACTORS; INTERLEUKIN-17; INTERLEUKINS; MICE; MICE, INBRED NOD; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES;

MUS;

EID: 78649965467     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2010.10.009     Document Type: Article

References (24)

1. Tisch R., Wang B. Dysregulation of T cell peripheral tolerance in type 1 diabetes. Adv. Immunol. 2008, 100:125-149.
2. Anderson M.S., Bluestone J.A. The NOD mouse: a model of immune dysregulation. Annu. Rev. Immunol. 2005, 23:447-485.
3. Datta S., Sarvetnick N.E. IL-21 limits peripheral lymphocyte numbers through T cell homeostatic mechanisms. PLoS One 2008, 3:e3118.
4. King C., Ilic A., Koelsch K., Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004, 117:265-277.
5. Spolski R., Kashyap M., Robinson C., Yu Z., Leonard W.J. IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. Proc. Natl. Acad. Sci. USA 2008, 105:14028-14033.
6. Sutherland A.P., Van Belle T., Wurster A.L., Suto A., Michaud M., Zhang D., Grusby M.J. And M. von Herrath, Interleukin-21 is required for the development of type 1 diabetes in NOD mice. Diabetes 2009, 58:1144-1155.
7. Ridgway W.M., Peterson L.B., Todd J.A., Rainbow D.B., Healy B., Burren O.S., Wicker L.S. Gene-gene interactions in the NOD mouse model of type 1 diabetes. Adv. Immunol. 2008, 100:151-175.
8. Emamaullee J.A., Davis J., Merani S., Toso C., Elliott J.F., Thiesen A., Shapiro A.M. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 2009, 58:1302-1311.
9. Jain R., Tartar D.M., Gregg R.K., Divekar R.D., Bell J.J., Lee H.H., Yu P., Ellis J.S., Hoeman C.M., Franklin C.L., Zaghouani H. Innocuous IFNgamma induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-17 production. J. Exp. Med. 2008, 205:207-218.
10. Martin-Orozco N., Chung Y., Chang S.H., Wang Y.H., Dong C. Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur. J. Immunol. 2009, 39:216-224.
11. Honkanen J., Nieminen J.K., Gao R., Luopajarvi K., Salo H.M., Ilonen J., Otonkoski T., Vaarala O. IL-17 immunity in human Type I Diabetes. J. Immunol. 2010, 185:1959-1967.
12. Brustle A., Heink S., Huber M., Rosenplanter C., Stadelmann C., Yu P., Arpaia E., Mak T.W., Kamradt T., Lohoff M. The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat. Immunol. 2007, 8:958-966.
13. Chen Q., Yang W., Gupta S., Biswas P., Smith P., Bhagat G., Pernis A.B. IRF-4 Binding Protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor. Immunity 2008, 299:899-911.
14. Huber M., Brustle A., Reinhard K., Guralnik A., Walter G., Mahiny A. E. von Low, and M. Lohoff, IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype. Proc. Natl. Acad. Sci. USA 2008, 105:20846-20851.
15. Biswas P., Bhagat G., Pernis A.B. IRF4 and its regulators: evolving insights into the pathogenesis of inflammatory arthritis?. Immunol. Rev. 2010, 233:79-96.
16. Biswas P.S., Gupta S., Chang E., Song L., Stirzaker R.A., Liao J.K., Bhagat G., Pernis A.B. Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J. Clin. Invest. 2010, 120:3280-3295.
17. Liu P.Y., Liao J.K. A method for measuring Rho kinase activity in tissues and cells. Methods Enzymol. 2008, 439:181-189.
18. Liao J.K., Seto M., Noma K. Rho kinase (ROCK) inhibitors. J. Cardiovasc. Pharmacol. 2007, 50:17-24.
19. Hattori T., Shimokawa H., Higashi M., Hiroki J., Mukai Y., Tsutsui H., Kaibuchi K., Takeshita A. Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation 2004, 109:2234-2239.
20. Gojo A., Utsunomiya K., Taniguchi K., Yokota T., Ishizawa S., Kanazawa Y., Kurata H., Tajima N. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 2007, 568:242-247.
21. Kikuchi Y., Yamada M., Imakiire T., Kushiyama T., Higashi K., Hyodo N., Yamamoto K., Oda T., Suzuki S., Miura S. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J. Endocrinol. 2007, 192:595-603.
22. Kolavennu V., Zeng L., Peng H., Wang Y., Danesh F.R. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 2008, 57:714-723.
23. Peng F., Wu D., Gao B., Ingram A.J., Zhang B., Chorneyko K., McKenzie R., Krepinsky J.C. RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes 2008, 57:1683-1692.
24. Arita R., Hata Y., Nakao S., Kita T., Miura M., Kawahara S., Zandi S., Almulki L., Tayyari F., Shimokawa H., Hafezi-Moghadam A., Ishibashi T. Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage. Diabetes 2009, 58:215-226.